• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

February 12, 2018
Company Drug/Device Medical Condition Status
Fibrocell Science FCX-013 moderate to severe localized scleroderma IND submitted to the FDA
Daiichi Sankyo U3-1402 metastatic or unresectable epidermal growth factor receptor-mutated non-small cell lung cancer Phase I trials initiated enrolling 60 subjects globally
Palatin Technologies PL-8177 ulcerative colitis and other inflammatory bowel diseases Phase I trials initiated enrolling 52 subjects
Phosplatin Therapeutics PT-112 relapsed or refractory multiple myeloma Phase I/II trials initiated
Gemphire gemcabene pediatric nonalcoholic fatty liver disease Phase IIa trials initiated enrolling 40 adolescent children between the ages of 12 and 17
OncBioMune Pharmaceuticals ProscaVax advanced prostate cancer Phase II trials initiated
Xcovery ensartinib (X-396) advanced malignant melanoma harboring alterations in ALK Phase II trials initiated
Endo International collagenase clostridium histolyticum cellulite Phase III trials initiated enrolling 840 women in the U.S.
Pharma Two B P2B001 early Parkinson's disease Phase III trials initiated enrolling 525 subjects
Tessa Therapeutics T cell immunotherapy nasopharyngeal cancer Phase III trials initiated enrolling 35 subjects
GlaxoSmithKline Bexsero meningitis B vaccine Breakthrough Therapy designation granted by the FDA
Sage Therapeutics SAGE-217 major depressive disorder Breakthrough Therapy designation granted by the FDA
Zogenix ZX008 (low-dose fenfluramine) seizures associated with Dravet syndrome Breakthrough Therapy designation granted by the FDA
MeiraGTx AAV2/8-hCARp.hCNGB3 (A002) achromatopsia due to mutations in the CNGB3 gene Rare Pediatric Disease designation granted by the FDA
Adhesys Medical VIVO surgical sealant Expedited Access Pathway designation granted by the FDA
Alnylam Pharmaceuticals patisiran hereditary ATTR amyloidosis NDA accepted and Priority Review granted by the FDA
Allergan Avycaz (ceftazidime and avibactam) hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia Expanded use approved by the FDA
Ferring Pharmaceuticals Zomacton (somatropin) human growth hormone deficiency FDA approved

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing